» Articles » PMID: 12188107

Animal Models of Anti-HIV Drugs Exposure During Pregnancy: Effects on Neurobehavioral Development

Overview
Specialty Psychiatry
Date 2002 Aug 22
PMID 12188107
Citations 5
Authors
Affiliations
Soon will be listed here.
Abstract

In the last 10 years, zidovudine (AZT) has become the main prophylactic therapy against vertical HIV-1 transmission. AIDS Clinical Trials Group (ACTG) 076 have demonstrated that the administration of AZT to HIV-infected women during their third trimester of pregnancy, trough labor and given orally to babies for 6 weeks, reduced by two-thirds the rate of vertical infection. Although the rapid diffusion of this regimen into clinical practice together with the implementation of HIV counseling and testing practices have dramatically reduced the vertical transmission rate in the US and Western Europe, there is a growing concern on the adverse effects of antiretroviral therapy on the fetus and the newborn. In fact, even though shorter regimen therapies that are less complex and expensive to implement in poor countries have been demonstrated as effective as ACTG 076 regimen, the distribution of the risk of vertical transmission in the developing countries is still very high. Consequently, a large number of unborns will be a candidate to developmental exposure to antiretroviral agents. To date, data on the transplacental mutagenicity, carcinogenicity and mitochondrial dysfunction induced by developmental exposure to AZT have been reported in several animal models. Furthermore, one study reported severe yet few human cases of cardiomyopathy and neurological disease likely associated with mitochondrial dysfunction in uninfected infants of seropositive mothers perinatally exposed to AZT. For all of these reasons, many investigations have been focusing on the assessment of the potential adverse effects of nucleoside reverse transcriptase (RT) inhibitors (NRTI) administration during development. A survey of the main results derived from clinical and animal studies is reported here, focusing on those neurobehavioral studies that have been looking for specific and/or aspecific changes in the nervous system induced by NRTI exposure in utero.

Citing Articles

Safety of perinatal exposure to antiretroviral medications: developmental outcomes in infants.

Sirois P, Huo Y, Williams P, Malee K, Garvie P, Kammerer B Pediatr Infect Dis J. 2013; 32(6):648-55.

PMID: 23340561 PMC: 3723344. DOI: 10.1097/INF.0b013e318284129a.


Reproductive health decision-making in perinatally HIV-infected adolescents and young adults.

Fair C, Wiener L, Zadeh S, Albright J, Mellins C, Mancilla M Matern Child Health J. 2012; 17(5):797-808.

PMID: 22736033 PMC: 3687209. DOI: 10.1007/s10995-012-1070-3.


The use of second-generation antipsychotics and the changes in physical growth in children and adolescents with perinatally acquired HIV.

Kapetanovic S, Aaron L, Montepiedra G, Sirois P, Oleske J, Malee K AIDS Patient Care STDS. 2009; 23(11):939-47.

PMID: 19827949 PMC: 2832650. DOI: 10.1089/apc.2009.0121.


Mitochondrial disorders among infants exposed to HIV and antiretroviral therapy.

Funk M, Belinson S, Pimenta J, Morsheimer M, Gibbons D Drug Saf. 2007; 30(10):845-59.

PMID: 17867723 DOI: 10.2165/00002018-200730100-00004.


Cerebral MR imaging in uninfected children born to HIV-seropositive mothers and perinatally exposed to zidovudine.

Tardieu M, Brunelle F, Raybaud C, Ball W, Barret B, Pautard B AJNR Am J Neuroradiol. 2005; 26(4):695-701.

PMID: 15814907 PMC: 7977132.